Investors should monitor upcoming catalysts: regulatory update for LMs in 1H 2026, interim THRIVE-3 data in 2H 2026, and completion of BCG-Unresponsive cohort enrollment in ADVANCED-2. The strong clinical data and extended runway reduce near-term dilution risk and increase probability of regulatory success.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $5.71entry
- T+1 · 8mo ago −1.93%α −1.82% · $5.60
- T+5 · 8mo ago −4.55%α −3.65% · $5.45
- T+20 · 7mo ago −8.58%α −8.43% · $5.22
- T+60 · 6mo ago −26.09%α −37.50% · $4.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protara Therapeutics reported strong interim clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC), showing a 68% complete response rate at six months in BCG-Unresponsive patients, alongside Breakthrough Therapy and Fast Track designations for lymphatic malformations. The company raised $86.3 million in a public offering, extending its cash runway into 2028, despite increased R&D and G&A expenses leading to a wider net loss. No revenue was generated as the company remains pre-commercial.
Key Financial Metrics
Key Facts
- TARA-002 demonstrated 68.2% complete response rate at six months in BCG-Unresponsive NMIBC patients (22 evaluable patients)
- Breakthrough Therapy and Fast Track designations received for TARA-002 in lymphatic malformations (LMs)
- Completed $86.3 million public offering, bringing cash, cash equivalents, and investments to $197.9 million as of December 31, 2025
- Cash runway now extends into 2028, funding key milestones including ADVANCED-2/3 and THRIVE-3 trials
- Net loss widened to $57.4 million in 2025 from $44.6 million in 2024 due to higher R&D and G&A spending
- No revenue reported, company remains clinical-stage with no commercial products
Financial Impact
Increased annual net loss by $12.8 million to $57.4M; raised $86.3M in gross proceeds, boosting cash reserves by ~120%
Risk Factors
- Clinical-stage biotech with no revenue; valuation dependent on trial outcomes
- Widening losses reflect advancing trials, but long-term profitability remains uncertain
- Market volatility could impact ability to raise capital if runway needs extension
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252699 |
Track record
13 reports on TARA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers